Introduction
============

Lung cancer is the main cause of cancer-related deaths in East Asia, accounting for one in four of all cancer-related deaths \[[@b1-crt-2015-135]\]. In Korea, an estimated 16,990 deaths in 2014 were caused by lung cancer, accounting for 22.7% of all cancer-related deaths \[[@b2-crt-2015-135]\]. The current first-line standard of care for advanced non-small cell lung cancer (NSCLC) is platinum-based doublet chemotherapy \[[@b3-crt-2015-135]\], although inhibitors of the epidermal growth factor receptor (EGFR) tyrosine kinase, such as gefitinib, are recommended in patients harboring activating *EGFR* mutations \[[@b4-crt-2015-135]-[@b6-crt-2015-135]\]. The phase 3 Iressa Pan-Asia Study (IPASS), which compared gefitinib monotherapy with combination chemotherapy as first-line therapy in East Asian patients, reported significantly longer progression-free survival (PFS) in patients who had *EGFR* mutations and were treated with gefitinib \[[@b7-crt-2015-135]\]. A subsequent phase 2 trial, in which combination chemotherapy followed by gefitinib or pemetrexed maintenance therapy was administered in East Asian patients with unknown EGFR status, reported longer PFS in patients receiving gefitinib than those receiving pemetrexed \[[@b8-crt-2015-135]\]. These findings may be attributed to the high frequency of *EGFR* mutations in East Asian patients with NSCLC \[[@b5-crt-2015-135],[@b7-crt-2015-135],[@b8-crt-2015-135]\].

The current randomized, open-label, phase 3 trial was designed for comparison of pemetrexed-cisplatin (PC) doublet chemotherapy followed by gefitinib maintenance therapy (PC/G) with gefitinib monotherapy in East Asian patients with NSCLC and unknown *EGFR* mutation status \[[@b9-crt-2015-135]\]. In the overall study population, there was no significant difference in PFS between treatment arms \[[@b9-crt-2015-135]\]. However, treatment response may differ in patients from various regions of East Asia or those with *EGFR* mutations that were not evident from the primary analysis. To further assess potential differences in treatment response in the East Asian population, we conducted a *post hoc* descriptive subgroup analysis of Korean patients from this phase 3 trial. The Korean subgroup comprised the largest proportion of patients in the original study. The aims of the subgroup analysis were to assess demographics and disposition of the Korean patients randomized in the study, compare the tolerability of PC/G therapy with gefitinib monotherapy in this subgroup, and assess the tumor response with respect to EGFR status for each treatment arm.

Materials and Methods
=====================

This study was a *post hoc* subgroup analysis of data from a randomized, open-label, phase 3 clinical trial (NCT0101 7874). Findings for the primary objective, which was to compare PFS in patients treated with PC/G with those treated with gefitinib monotherapy, were reported previously by Yang et al. \[[@b9-crt-2015-135]\]. The study was conducted in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki; all patients provided informed consent. Patient eligibility criteria included age ≥ 18 years, chemonaïve, East Asian, and light ex-smokers/never-smokers with advanced NSCLC. Patients were assigned (1:1) to receive either PC/G therapy (PC \[P, 500 mg/m^2^; C, 75 mg/m^2^\] for six 21-day induction cycles, then gefitinib \[250 mg/day\] maintenance therapy) or gefitinib monotherapy (G \[250 mg/day\], administered until progression, discontinuation, or death). Treatment-emergent adverse events (TEAEs; possibly drug-related) and serious adverse events were classified according to MedDRA (ver. 15.1) and graded. Safety analyses were performed on the safety population, which included all patients who received ≥ 1 dose of the study drug. Tumor response, conducted on the tumor response-qualified population (patients with lesion measurements taken at baseline and at least 1 other time point), was measured as change in lesion sum from baseline at best response. Change in lesion sum was determined as the change from baseline in the sum of the largest diameter of each lesion (up to a maximum of 10 lesions per patient). Analysis of patient tissue was performed retrospectively for *EGFR* mutations.

Results
=======

1. Patient disposition
----------------------

A total of 253 patients were enrolled in the phase 3 study, 120 of whom were enrolled in Korea ([Fig. 1](#f1-crt-2015-135){ref-type="fig"}). Of the 120 Korean patients enrolled in the study, 114 patients were randomly assigned to treatment: 54 patients were assigned to PC/G (3 of whom were not treated); 60 patients were assigned gefitinib monotherapy. Thirty-three patients in the PC/G arm received gefitinib maintenance therapy and 28 patients in the gefitinib arm received more than six cycles of treatment.

2. Patient demographics
-----------------------

Baseline patient demographics were balanced between arms and similar to those reported for the overall study population ([Table 1](#t1-crt-2015-135){ref-type="table"}) \[[@b9-crt-2015-135]\]. All Korean patients had adenocarcinoma, most were never-smokers (93.9%), had stage IV disease (91.2%), and had a Eastern Cooperative Oncology Group (ECOG) performance status of 1 (57.0%) ([Table 1](#t1-crt-2015-135){ref-type="table"}).

3. Treatment duration
---------------------

The median number of treatment cycles completed overall was 7.0 and 6.0 for PC/G and gefitinib monotherapy, respectively. The median number of treatment cycles was 6.0 for both treatment arms during the induction period, and 4.0 and 7.5 for PC/G and gefitinib monotherapy, respectively, during the maintenance period.

4. Response to therapy by EGFR status
-------------------------------------

The change in lesion sum from baseline was calculable for 47 patients in the PC/G arm and 53 patients in the gefitinib arm. Lesion sum was reduced by treatment with PC/G in the majority of Korean patients with NSCLC, regardless of *EGFR* mutation status ([Figs. 2A](#f2-crt-2015-135){ref-type="fig"} and [3A](#f3-crt-2015-135){ref-type="fig"}). In this selected population, lesion sum was reduced by gefitinib monotherapy in the subgroup of Korean patients who were confirmed as EGFR positive (n=8) ([Figs. 2B](#f2-crt-2015-135){ref-type="fig"} and [3B](#f3-crt-2015-135){ref-type="fig"}). In contrast, gefitinib monotherapy had no positive effect on lesion sum in the subgroup of Korean patients who were EGFR negative (n=3) ([Figs. 2B](#f2-crt-2015-135){ref-type="fig"} and [3B](#f3-crt-2015-135){ref-type="fig"}).

5. Adverse events
-----------------

Overall, 92 of 111 patients (82.9%) reported at least 1 TEAE during treatment. Treatment discontinuation due to adverse events (AEs) was low (PC/G, 1/51 \[2.0%\]; gefitinib, 7/60 \[11.7%\]). Few patients (PC/G, 16/51 \[31.4%\]; gefitinib, 7/60 \[11.7%\]) reported severe (grades 3-4) TEAEs during the overall treatment period; the most frequent was neutropenia in the PC/G treatment arm and elevated alanine aminotransferase in the gefitinib treatment arm. No patients reported grade 5 TEAEs ([Table 2](#t2-crt-2015-135){ref-type="table"}).

Conclusion
==========

Patient demographics and AEs in Korean patients with NSCLC were similar to those reported in the overall study population \[[@b9-crt-2015-135]\]. A slightly higher proportion of Korean patients experienced grades 3-4 hematologic TEAEs following PC/G treatment compared with the overall population, but, overall, both PC/G and gefitinib monotherapy were well tolerated in Korean patients with NSCLC. Although a limited number of samples were available for EGFR testing, *post hoc* analysis of tumor response based on *EGFR* mutation status showed that PC/G treatment consistently reduced lesion sum in patients with and without *EGFR* mutations, but gefitinib monotherapy had no effect in patients with EGFR wild-type. The findings of this Korean patient subgroup analysis confirmed that PC/G and gefitinib monotherapy showed favorable tolerability in patients with advanced NSCLC; however, such patients with EGFR wild-type may not benefit from gefitinib monotherapy.
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###### 

Baseline patient demographics for the Korean patient subgroup

                                   PC/G (n=54)         Gefitinib (n=60)    Total (n=114)       p-value
  -------------------------------- ------------------- ------------------- ------------------- ---------
  **Sex**                                                                                      
   Male                            10 (18.5)           13 (21.7)           23 (20.2)           0.816
   Female                          44 (81.5)           47 (78.3)           91 (79.8)           
  **Age (yr)**                                                                                 
   Mean (range)                    59.43 (30.7-80.7)   62.16 (30.5-79.2)   60.87 (30.5-80.7)   0.161
   \< 65                           35 (64.8)           36 (60.0)           71 (62.3)           0.699
   ≥ 65                            19 (35.2)           24 (40.0)           43 (37.7)           
  **Smoking status**                                                                           
   Never-smoker                    52 (96.3)           55 (91.7)           107 (93.9)          0.443
   Light ex-smoker                 2 (3.7)             5 (8.3)             7 (6.1)             
  **Stage of disease**                                                                         
   IIIB                            4 (7.4)             6 (10.0)            10 (8.8)            0.746
   IV                              50 (92.6)           54 (90.0)           104 (91.2)          
  **ECOG performance status**                                                                  
   0                               24 (44.4)           25 (41.7)           49 (43.0)           0.850
   1                               30 (55.6)           35 (58.3)           65 (57.0)           
  ***EGFR* mutation status**                                                                   
   Patients who provided samples   20 (37.0)           20 (33.3)           40 (35.1)           \-
   *EGFR* mutated                  4 (7.4)             8 (13.3)            12 (10.5)           
   *EGFR* not mutated              3 (5.6)             5 (8.3)             8 (7.0)             
   *EGFR* unknown                  13 (24.1)           7 (11.7)            20 (17.5)           

Values are presented as number (%) unless otherwise indicated. PC/G, pemetrexed-cisplatin/gefitinib; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor.

###### 

Adverse events reported in at least 5% of Korean patients in either treatment arm during the induction phase of treatment

                                                               Pemetrexed plus cisplatin (n=51)   Gefitinib (n=60)               
  ------------------------------------------------------------ ---------------------------------- ------------------ ----------- ----------
  **Patients with ≥ 1 TEAE**                                   30 (58.8)                          13 (25.5)          41 (68.3)   7 (11.7)
  **Hematologic**                                                                                                                
   Neutrophils/granulocytes                                    5 (9.8)                            9 (17.6)           0           0
  **Non-hematologic**                                                                                                            
   ALT                                                         0                                  1 (2.0)            4 (6.7)     3 (5.0)
   AST                                                         0                                  0                  5 (8.3)     2 (3.3)
   Anorexia                                                    15 (29.4)                          1 (2.0)            3 (5.0)     0
   Constipation                                                4 (7.8)                            0                  0           0
   Diarrhoea                                                   6 (11.8)                           0                  12 (20.0)   2 (3.3)
   Dry skin                                                    0                                  0                  8 (13.3)    0
   Fatigue^[a)](#tfn3-crt-2015-135){ref-type="table-fn"}^      3 (5.9)                            1 (2.0)            6 (10.0)    0
   Hair loss                                                   5 (9.8)                            0                  2 (3.3)     0
   Hemorrhage^[a)](#tfn3-crt-2015-135){ref-type="table-fn"}^   3 (5.9)                            0                  2 (3.3)     0
   Mucositis^[a)](#tfn3-crt-2015-135){ref-type="table-fn"}^    1 (2.0)                            0                  6 (10.0)    0
   Nausea                                                      24 (47.1)                          2 (3.9)            4 (6.7)     0
   Neuropathy, sensory                                         9 (17.6)                           0                  2 (3.3)     0
   Pain^[a)](#tfn3-crt-2015-135){ref-type="table-fn"}^         6 (11.8)                           0                  2 (3.3)     1 (1.7)
   Pruritus, itching                                           5 (9.8)                            0                  18 (30.0)   0
   Skin rash^[a)](#tfn3-crt-2015-135){ref-type="table-fn"}^    3 (5.9)                            0                  31 (51.7)   1 (1.7)
   Vomiting                                                    11 (21.6)                          3 (5.9)            0           0

Values are presented as number (%). ALT, alanine aminotransferase; AST, aspartate transaminase; TEAE, treatment-emergent adverse event. Events are maximum grade per National Cancer Institute--Common Terminology Criteria for Adverse Events (NCI-CTCAE, ver. 3.0).

Fatigue, hemorrhage, mucositis, pain, and skin rash are combined from some specific CTCAE terms.
